CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
While the use of cell therapies to treat hematological malignancies has been hailed as a clinical breakthrough, this promising new class of therapies has been far less effective in treating solid ...
AI is transforming drug discovery, but accurately predicting patient responses remains challenging. Considering the ongoing need to connect drugs with the right patients and rising drug costs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results